Creo Medical Group PLC
AIM:CREO Stock Report
Creo Medical Group Future Growth
Future criteria checks 0/6 Creo Medical Group's revenue is forecast to decline at 4.9% per annum while its annual earnings are expected to grow at 41% per year. EPS is expected to grow by 45.6% per annum. Return on equity is forecast to be -14.7% in 3 years.
Key information
41.0%
Earnings growth rate
Medical Equipment earnings growth 22.8% Revenue growth rate -4.9% Future return on equity -14.7% Analyst coverage Low
Last updated 24 Oct 2024
Recent future growth updates
Consensus EPS estimates fall by 24% Oct 25
Price target decreased by 28% to UK£0.57 Oct 24
Consensus EPS estimates fall by 11% Oct 07
No longer forecast to breakeven Oct 01
Consensus EPS estimates fall by 21% May 22
Forecast to breakeven in 2026 May 07
Show all updates
New minor risk - Shareholder dilution Oct 27
Consensus EPS estimates fall by 24% Oct 25
Chairman recently bought UK£700k worth of stock Oct 25
Price target decreased by 28% to UK£0.57 Oct 24
New minor risk - Market cap size Oct 15
Consensus EPS estimates fall by 11% Oct 07
First half 2024 earnings released: UK£0.034 loss per share (vs UK£0.044 loss in 1H 2023) Oct 02
New minor risk - Shareholder dilution Oct 02
No longer forecast to breakeven Oct 01
New minor risk - Share price stability Sep 30 Micro-Tech (NL) International B.V. entered into a binding agreement to acquire 51% stake in Creo Medical, S.L.U. from Creo Medical Group PLC (AIM:CREO) for €36.7 million. Sep 20
Creo Medical Group PLC (LON:CREO) Screens Well But There Might Be A Catch Sep 19
New major risk - Financial position Sep 18
Creo Medical Group PLC, Annual General Meeting, Jun 26, 2024 Jun 02
Consensus EPS estimates fall by 21% May 22
Full year 2023 earnings: EPS and revenues miss analyst expectations May 16 Creo Medical Group plc Announces Board Changes May 15
Forecast to breakeven in 2026 May 07
New minor risk - Financial data availability May 03
Creo Medical Group PLC to Report Fiscal Year 2023 Results on May 15, 2024 Apr 26
New minor risk - Profitability Mar 11
Market Cool On Creo Medical Group PLC's (LON:CREO) Revenues Pushing Shares 26% Lower Mar 02
Creo Medical Group plc Announces Microwave Lung Ablation Update Mar 01
New minor risk - Share price stability Feb 07
Creo Medical Group plc Announces Continued Progress on the Phased Market Release of Its Latest Device, Speedboat® UltraSlim Feb 01
Forecast to breakeven in 2026 Dec 31
Revenues Tell The Story For Creo Medical Group PLC (LON:CREO) As Its Stock Soars 29% Dec 29
Creo Medical Group plc Announces First Use of Speedboat UltraSlim in the USA Dec 15
Creo Medical Group PLC Announces the Initiation of Its Commercial Launch of Speedboat Ultraslim Dec 13
Creo Medical Group plc Receives 510(K) Clearance from the Us Food & Drug Administration for Its Speedboat Ultraslim Device Nov 02
Creo Medical Group plc Announces EU Launch Accelerated by 18 Months Eu Regulatory Pathway for Launch Early 2024 Oct 26
Is Creo Medical Group (LON:CREO) Weighed On By Its Debt Load? Oct 06
First half 2023 earnings released: UK£0.044 loss per share (vs UK£0.074 loss in 1H 2022) Sep 17
Creo Medical Group PLC to Report First Half, 2023 Results on Sep 12, 2023 Sep 05
Creo Medical Group PLC, Annual General Meeting, Jun 27, 2023 May 27
Creo Medical Group plc Announces First In-Human Milestone Reaches for Microblate Flex as Part of Lung Tissue Ablation Clinical Study May 23
Full year 2022 earnings: EPS misses analyst expectations Apr 27
Key Executive recently bought UK£543k worth of stock Mar 15
Creo Medical Group PLC, Annual General Meeting, Mar 08, 2023 Feb 18 Creo Medical Group PLC has completed a Follow-on Equity Offering in the amount of £28.5 million. Feb 17
Creo Medical Group PLC, Annual General Meeting, Mar 08, 2023 Feb 16
Less than half of directors are independent Nov 16
Creo Medical Limited, Annual General Meeting, Jun 28, 2022 Jun 29
Creo Medical Limited to Report Fiscal Year 2021 Results on May 23, 2022 May 17
Less than half of directors are independent Apr 27
Creo Medical Limited has completed a Follow-on Equity Offering in the amount of £5.06601 million. Sep 08
Creo Medical Limited has completed a Follow-on Equity Offering in the amount of £31.250001 million. Aug 14
New 90-day high: UK£2.23 Feb 17
Creo Medical (LON:CREO) Is In A Good Position To Deliver On Growth Plans Feb 03
New 90-day high: UK£2.12 Jan 23
Creo Medical Group plc Receives US FDA clearance for MicroBlate™ Flex device Jan 08
How Many Creo Medical Limited (LON:CREO) Shares Do Institutions Own? Dec 09
New 90-day high: UK£2.08 Dec 09
New 90-day low: UK£1.67 Oct 13
First half earnings released Sep 29
New 90-day low: UK£1.72 Sep 19
Earnings and Revenue Growth Forecasts AIM:CREO - Analysts future estimates and past financials data (GBP Millions) Date Revenue Earnings Free Cash Flow Cash from Op Avg. No. Analysts 12/31/2026 28 -11 -14 -13 2 12/31/2025 32 -11 -16 -15 3 12/31/2024 34 -19 -2 -16 3 6/30/2024 30 -22 -22 -20 N/A 3/31/2024 31 -22 -22 -21 N/A 12/31/2023 31 -22 -23 -22 N/A 9/30/2023 30 -23 -24 -22 N/A 6/30/2023 29 -25 -25 -23 N/A 3/31/2023 28 -26 -27 -24 N/A 12/31/2022 27 -27 -28 -25 N/A 9/30/2022 27 -28 -33 -27 N/A 6/30/2022 26 -28 -38 -30 N/A 3/31/2022 26 -26 -35 -28 N/A 12/31/2021 25 -25 -32 -26 N/A 9/30/2021 24 -23 -26 -22 N/A 6/30/2021 22 -21 -19 -19 N/A 3/31/2021 16 -21 -18 -18 N/A 12/31/2020 9 -20 -17 -16 N/A 9/30/2020 5 -19 -17 -16 N/A 6/30/2020 0 -17 -17 -16 N/A 3/31/2020 0 -17 -15 -14 N/A 12/31/2019 0 -16 -13 -12 N/A 6/30/2019 0 -13 -14 -13 N/A 3/31/2019 0 -12 -12 -11 N/A 12/31/2018 N/A -10 -10 -10 N/A 12/31/2017 0 -8 N/A -9 N/A 9/30/2017 0 -8 N/A -8 N/A 6/30/2017 N/A -8 N/A -7 N/A 6/30/2016 1 -5 N/A -5 N/A 2/29/2016 1 -3 N/A -3 N/A 2/28/2015 N/A -2 N/A -2 N/A 2/28/2014 1 -2 N/A -1 N/A
Show more
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CREO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CREO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CREO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CREO's revenue is expected to decline over the next 3 years (-4.9% per year).
High Growth Revenue: CREO's revenue is forecast to decline over the next 3 years (-4.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CREO is forecast to be unprofitable in 3 years.
Discover growth companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
